Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study (vol 9, pg 363, 2018)

被引：1
|
作者：
Ciresi, Alessandro [1 ]
Vigneri, Enrica [1 ]
Radellini, Stefano [1 ]
Panto, Felicia [1 ]
Giordano, Carla [1 ]
机构：
[1] Univ Palermo, Biomed Dept Internal & Specialist Med, Endocrinol Sect, Palermo, Italy
来源：
DIABETES THERAPY | 2018年 / 9卷 / 03期
关键词：
D O I：
10.1007/s13300-018-0423-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Author Correction to: Diabetes Ther (2018) 9:363-371.
引用
收藏
页码：1413 / 1413
页数：1
相关论文
共 11 条
  • [1] Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
    Ciresi, Alessandro
    Vigneri, Enrica
    Radellini, Stefano
    Panto, Felicia
    Giordano, Carla
    DIABETES THERAPY, 2018, 9 (01) : 363 - 371
  • [2] Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
    Alessandro Ciresi
    Enrica Vigneri
    Stefano Radellini
    Felicia Pantò
    Carla Giordano
    Diabetes Therapy, 2018, 9 : 363 - 371
  • [3] Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
    Alessandro Ciresi
    Enrica Vigneri
    Stefano Radellini
    Felicia Pantò
    Carla Giordano
    Diabetes Therapy, 2018, 9 : 1413 - 1413
  • [4] Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey - GALATA study
    Ayvaz, Goksun
    Keskin, Lezzan
    Akin, Fulya
    Dokmetas, Hatice Sebile
    Tasan, Ertugrul
    Ar, Idilhan Baloglu
    Uren, Emel
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (04) : 623 - 632
  • [5] Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: A retrospective real-life study in 131 patients (vol 13, pg 332, 2018)
    Hemmer, A.
    Maiter, D.
    Buysschaert, M.
    Preumont, V.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (01) : 469 - 469
  • [6] Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study
    Penfornis, A.
    Bourdel-Marchasson, I.
    Quere, S.
    Dejager, S.
    DIABETES & METABOLISM, 2012, 38 (06) : 550 - 557
  • [7] Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study' (vol 32, pg 1900, 2011)
    Schramm, T. K.
    Gislason, G. H.
    Vaag, A.
    Rasmussen, J. N.
    Folke, F.
    Hansen, M. L.
    Fosbol, E. L.
    Kober, L.
    Norgaard, M. L.
    Madsen, M.
    Hansen, P. R.
    Torp-Pedersen, C.
    EUROPEAN HEART JOURNAL, 2012, 33 (10) : 1183 - 1183
  • [8] Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
    Vera Frison
    Natalino Simioni
    Alberto Marangoni
    Sara Balzano
    Carmela Vinci
    Luciano Zenari
    Lorena De Moliner
    Federica Tadiotto
    Michele D’Ambrosio
    Loris Confortin
    Narciso Marin
    Simonetta Lombardi
    Silvana Costa
    Giuseppe Prosperini
    Annunziata Lapolla
    Diabetes Therapy, 2018, 9 : 2201 - 2208
  • [9] Incidence of Cardiovascular Outcomes in Type 2 Diabetic Patients Treated With Insulinglutisine or Other Rapid Acting Insulin Analogs Under Real-life Conditions: a Retrospective Database Analysis
    Scholz, B. -M.
    Dippel, F. -W.
    DIABETOLOGIE UND STOFFWECHSEL, 2012, 7 (04) : 302 - 307
  • [10] Clinical Impact of 5Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
    Frison, Vera
    Simioni, Natalino
    Marangoni, Alberto
    Balzano, Sara
    Vinci, Carmela
    Zenari, Luciano
    De Moliner, Lorena
    Tadiotto, Federica
    D'Ambrosio, Michele
    Confortin, Loris
    Marin, Narciso
    Lombardi, Simonetta
    Costa, Silvana
    Prosperini, Giuseppe
    Lapolla, Annunziata
    DIABETES THERAPY, 2018, 9 (06) : 2201 - 2208
12